San Diego, CA, United States of America

Wei Xiao

This inventor holds 21 USPTO granted patents and 3 published patent applications and 5 EPO patents, primarily in Pharmaceutical Modulators. Top assignees: Janssen Pharmaceutica Nv, Ortho-Mcneil Pharmaceutical Corp., Agouron Pharmaceuticals, Inc.. Active years: 2003-2016.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Wei Xiao. Retrieved from https://idiyas.com/inventor/wei-xiao-27drlozs

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 21 

% Patents Active = 90.5

 

Average Co-Inventor Count = 5.6

ph-index = 5

Forward Citations = 58(Granted Patents)


Company Filing History:


Years Active: 2003-2016

Loading Chart...
Loading Chart...
Areas of Expertise:
TRPV1
Fatty Acid Amide Hydrolase
TRPA1
Heterocyclic Compounds
Piperazinyl Ureas
Imidazolo-Compounds
Cyclin-Dependent Kinase Inhibitors
Phenylalkynes
Aryl-Hydroxyethylamino-Pyrimidines
Piperidinyl Ureas
Non-Imidazole Compounds
Thiazolopyrimidine
21 patents (USPTO):Explore Patents

Title: Innovations and Contributions of Wei Xiao in Pharmaceutical Science

Introduction

Wei Xiao is a prominent inventor located in San Diego, California, known for his significant contributions to pharmaceutical science. With an impressive portfolio of 21 patents, his work primarily revolves around innovative compounds targeting various medical conditions. His inventions have the potential to address a range of health issues, from pain management to treating complex neurological disorders.

Latest Patents

Wei Xiao's recent patents showcase his expertise in developing novel compounds. One of his notable patents includes the invention of imidazolo-, oxazolo-, and thiazolopyrimidine modulators of TRPV1. These compounds have applications in pharmaceutical compositions and are designed to treat disease states and conditions mediated by TRPV1 activity, such as pain, arthritis, itching, cough, asthma, and inflammatory bowel disease.

Additionally, Xiao has developed piperazinyl and piperidinyl urea compounds that function as inhibitors of fatty acid amide hydrolase (FAAH). These innovative compounds are intended for use in the treatment of various disorders, including anxiety, pain, inflammation, sleep disorders, eating disorders, and movement disorders like multiple sclerosis.

Career Highlights

Wei Xiao has an extensive background in pharmaceutical research, having worked with esteemed companies such as Janssen Pharmaceutica NV and Ortho-McNeil Pharmaceutical Corporation. His experience in these organizations has significantly contributed to his proficiency in drug development and innovation within the pharmaceutical industry.

Collaborations

Throughout his career, Wei Xiao has collaborated with talented colleagues, including Richard Apodaca and J. Guy Breitenbucher. These partnerships have fostered a creative environment, leading to advancements in therapeutic strategies and the creation of impactful pharmaceutical solutions.

Conclusion

Wei Xiao's contributions to the field of pharmaceutical science through his patents and collaborative efforts illustrate his dedication to advancing medicine. His innovative work not only enhances our understanding of complex medical conditions but also paves the way for effective treatments, showcasing the critical role of inventors in the healthcare arena.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…